Radiopharmaceuticals and Immunotherapeutics
for Novel Targets from our
NANOBODY
SYNTHETIC LIBRARY PLATFORM
ImmunoPET and Immunotherapy for Fibrosis and Cancer
“Nanobody” is a registered trademark of Ablynx NV, Sanofi
Cortalix
Cortalix is a clinical-stage biopharmaceuticals company developing PET-imaging diagnostics, targeted radiotherapeutics and immunotherapeutics for novel targets based on its proprietary nanobody* (single-domain antibody) platforms.
Cortalix operates on a three-pillar business model:
1: Internal programs
Cortalix has a growing number of Internal Programs of selected nanobody clinical candidates targeting PDGFRA, PDGFRB, FAP, IGF2R, and EGFR for immuno-PET and immunotherapy in fibrosis and cancer. These programs are available for licensing.
2: Partner programs
Cortalix collaborates with other pharmaceutical companies and academic research groups in Partner Programs to screen and select new suitable nanobody candidates for novel targets. We can develop these nanobodies into fully-fledged radiopharmaceuticals and immunotherapeutic applications.
3: Services
Finally, we offer stand-alone nanobody selection and development projects on a fee-for-service basis for CROs, pharma companies and research groups for very different applications, including targeted therapy, immunotherapy, but also for research tools and bioanalytical applications such as immunohistochemistry, fluorescence imaging, tailored affinity columns, and ELISA development and validation.
Latest open positions
VP Business Development
Job description: VP Business Development.Type: 40% – 60%.Location: Innolab Agrifood, Groningen, The Netherlands.Date: Immediate.About the role At Cortalix, The VP Business Development is responsible for managing and developing Cortalix’s business development towards...
Internship Life Sciences for 2nd half 2024, starting August
Job description: Internship Life Sciences for 2nd half of 2024, starting August 2024.Type: 80% – 100%, dependent on requirements master or bachelor program.Location: Innolab Agrifood, Groningen, The Netherlands.Date: Immediate.About the role At Cortalix we can support...
Latest news and events
Cortalix will present at TRP Berlin, Germany, 5 – 7 December 2023
Herman Steen, CEO of Cortalix, will present on "Novel Fibrosis Targets for Molecular Imaging of Fibrogenesis & Fibrotic Cancers" at the 5th Targeted Radiopharmaceuticals Summit EU 2023, December 5 - 7, 2023 in Berlin, Germany. For more information about Cortalix:...
Cortalix is awarded a EUROSTARS grant and joins the existing consortium on molecular diagnostic PET-imaging of colorectal cancer
Cortalix will join the existing consortium on a EUROSTARS grant of EUR 1.7 million for colorectal cancer molecular PET-imaging. EUROSTARS is a joint program of EUREKA and the European Commission, co-funded by the national budgets of 36 EUROSTARS Participating and...
CONTACT US
If you would like to know more about our organization, or would like to know how we can support your projects, please complete the contact form. We will contact you shortly.